<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87300">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01842451</url>
  </required_header>
  <id_info>
    <org_study_id>VX13-135-105</org_study_id>
    <nct_id>NCT01842451</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Partially-Blind, Dose-Ranging Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Treatment-Naïve Adult Subjects With Genotype 1 Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <authority>New Zealand: Medsafe</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of
      VX-135 and Daclatasvir in Treatment-Naïve Adult Subjects With Genotype 1 Chronic Hepatitis C
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The safety and tolerability as assessed by adverse events (AEs), vital signs, 12-lead electrocardiograms (ECGs), echocardiograms, and laboratory assessments</measure>
    <time_frame>Up to 64 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects who have a sustained virologic response (SVR; i.e., HCV RNA concentration below the lower limit of quantitation [&lt;LLOQ; &lt;25 IU/mL]) at 4 weeks after the last planned dose of treatment (SVR4)</measure>
    <time_frame>Up to 20 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects who have an SVR at 12 weeks after the last planned dose of treatment (SVR12)</measure>
    <time_frame>Up to 28 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects who have an SVR at 44 weeks after the last planned dose of treatment (SVR24)</measure>
    <time_frame>Up to 40 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects who have virologic relapse</measure>
    <time_frame>Up to 64 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects who have virologic breakthrough</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The amino acid sequence of the nonstructural NS5A and NS5B proteins in subjects who have treatment failure</measure>
    <time_frame>Up to 64 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects who achieve SVR12 by HCV genotype 1 subtype (1a versus non-1a)</measure>
    <time_frame>Up to 28 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects who achieve SVR12 by IL-28B genotype (CC versus non-CC)</measure>
    <time_frame>Up to 28 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>CHC</condition>
  <condition>HCV</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>VX-135 High Dose with Daclatasvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks of a high dose of VX-135 in combination with Daclatasvir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VX-135 Low Dose with Daclatasvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks of a low dose of VX-135 in combination with Daclatasvir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-135</intervention_name>
    <arm_group_label>VX-135 High Dose with Daclatasvir</arm_group_label>
    <arm_group_label>VX-135 Low Dose with Daclatasvir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <arm_group_label>VX-135 High Dose with Daclatasvir</arm_group_label>
    <arm_group_label>VX-135 Low Dose with Daclatasvir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have genotype 1 CHC and evidence of HCV infection at least 6 months
             before screening

          -  Subjects must be treatment-naïve and have not received prior treatment with any
             interferon, immunomodulatory agent, or DAA for HCV

        Exclusion Criteria:

          -  Evidence of cirrhosis

          -  History or other clinical evidence of significant or unstable cardiac disease

          -  Any other cause of significant liver disease in addition to hepatitis C

          -  Creatinine clearance ≤50 mL/min using the Cockcroft-Gault equation at screening

          -  Female subjects who are pregnant or nursing
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>New Zealand</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Zealand</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 2, 2014</lastchanged_date>
  <firstreceived_date>April 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
